Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
INVO Fertility ( (IVF) ) has provided an announcement.
On December 30, 2025, INVO Fertility announced a realignment of its executive leadership team to better support its growth strategy centered on acquiring and establishing fertility clinics and related businesses. Company controller Terah Krigsvold, with the firm since 2020, was promoted to chief financial officer, succeeding Andrea Goren, who moved into the roles of chief business officer and chief executive officer of INVO Centers LLC, the subsidiary overseeing fertility clinics. Management emphasized that the changes are intended to maintain continuity in finance while freeing Goren to leverage his experience in financing and acquisition transactions to drive clinic acquisitions, new clinic launches, and related legal, diligence, and investor-relations activities, underscoring a sharper operational focus on scaling the clinic network and moving the business toward profitability.
The most recent analyst rating on (IVF) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on INVO Fertility stock, see the IVF Stock Forecast page.
Spark’s Take on IVF Stock
According to Spark, TipRanks’ AI Analyst, IVF is a Neutral.
INVO Fertility’s overall stock score is primarily impacted by its financial performance challenges, including profitability and cash flow issues. The technical analysis indicates bearish momentum, further weighing down the score. However, recent corporate events provide a positive outlook, suggesting potential for future growth and improved market positioning.
To see Spark’s full report on IVF stock, click here.
More about INVO Fertility
INVO Fertility, Inc. is a healthcare services fertility company focused on expanding access to assisted reproductive technology by building, acquiring and operating fertility clinics, including its branded INVO Centers that primarily offer the intravaginal culture (IVC) procedure enabled by its proprietary INVOcell medical device, as well as profitable U.S.-based in vitro fertilization (IVF) clinics. The company currently operates two INVO Centers and one IVF clinic in the United States and also sells and distributes INVOcell to third-party fertility clinics, positioning its IVC procedure as a more connected, affordable alternative to traditional IVF and a more effective option than intrauterine insemination.
Average Trading Volume: 964,659
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.41M
For detailed information about IVF stock, go to TipRanks’ Stock Analysis page.